CytomX Therapeutics
CTMX
111 hedge funds and large institutions have $561M invested in CytomX Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 40 reducing their positions, and 26 closing their positions.
8,350% more call options, than puts
Call options by funds: $169K | Put options by funds: $2K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.14% less ownership
Funds ownership: 84.06% → 83.92% (-0.14%)
8% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 40
9% less funds holding
Funds holding: 122 → 111 (-11)
20% less capital invested
Capital invested by funds: $698M → $561M (-$137M)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.9M |
| 2 |
RI
RTW Investments
New York
|
+$13.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$3.71M |
| 5 |
AG
Artal Group
Luxembourg
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.55M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$6.17M |
| 5 |
CC
Casdin Capital
New York
|
-$3.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FRM
126
Fox Run Management
Greenwich,
Connecticut
| – | -$225K | -12,149 | Closed |
|
|
OSAM
127
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$175K | -9,570 | Closed |
|
|
NIT
128
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$82K | -4,500 | Closed |
|
129
Pacer Advisors
Malvern,
Pennsylvania
| – | -$82K | -4,431 | Closed |
|
|
QT
130
Quantbot Technologies
New York
| – | -$74K | -4,046 | Closed |
|
131
Walleye Trading
New York
| – | -$46K | -2,500 | Closed |
|
132
Schroder Investment Management Group
London,
United Kingdom
| – | -$44K | -2,366 | Closed |
|
|
GC
133
Grace Capital
Quincy,
Massachusetts
| – | -$35K | -1,888 | Closed |
|
|
MAM
134
Meeder Asset Management
Dublin,
Ohio
| – | -$34K | -1,764 | Closed |
|
|
PHK
135
Point72 Hong Kong
Hong Kong
| – | -$25K | -1,347 | Closed |
|
|
PCM
136
Prelude Capital Management
New York
| – | -$1K | -72 | Closed |
|
137
AssetMark Inc
Concord,
California
| – | -$1K | -44 | Closed |
|
CTMX Hedge Fund Activity: Q4 2018 in Review
111 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2018, worth a combined $561M — down 20% from $698M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CTMX and 16 opened new positions — a net loss of 10 holders — while 40 trimmed existing stakes and 37 added.
The largest buyer was Wellington Management Group, adding an estimated $31.9M. The largest seller was Vanguard Group, cutting an estimated $15.6M.
- 111 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2018, down from 122 in Q3 2018.
- Funds reported $561M of CytomX Therapeutics stock for Q4 2018, down 20% quarter-over-quarter.
- 16 funds opened new CytomX Therapeutics positions in Q4 2018 and 26 closed out, a net change of -10 holders.
- The largest CytomX Therapeutics buyer in Q4 2018 was Wellington Management Group, an estimated $31.9M added.
- The largest CytomX Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2018.